PROGRESSIVE'S EVENING STROLL DATE: 17 November, 2025

Market Snapshot:

A range-bound activity dominated the morning trade, but leadership from the Banking and Auto counters helped the Index break out of its intraday range and move higher, ultimately ending the session at 26,013.45 with gains of 103.40 points. Alongside Auto and Banking, the Media and Energy sectors also outperformed. The Broader Markets showed a strong trend, with Mid and Smallcaps outperforming the Frontline Index.

HOW THE DAY TRENDED

INDICES

Index	Close	Points	%Chg.
Sensex	84950.95	388.17	**0.46**
Nifty50	26013.45	103.40	**0.40**
Nifty Midcap 100	61180.50	441.30	**0.73**
Nifty Small Cap 100	18347.60	95.10	**0.52**

SECTORAL GAINERS / LOSERS

Sectors	Close	Points	%Chg.
NIFTY PSU BANK	8491.65	91.75	**1.09**
NIFTY AUTO	27472.65	232.85	**0.85**
NIFTY BANK	58962.70	445.15	**0.76**
NIFTY ENERGY	36441.85	180.75	**0.50**

NIFTY TOP GAINERS / LOSERS

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
ETERNAL	309.55	**1.91**	TMPV	372.70	**(4.73)**
TATA CONSUMER	1178.90	**1.82**	JIO FIN	312.00	**(0.92)**
MAX HEALTHCARE	1121.60	**1.68**	ULTRATECH	11778.00	**(0.81)**
EICHER MOTORS	6799.00	**1.55**	ASIAN PAINTS	2887.90	**(0.64)**

INDICES LEVELS FOR November 18, 2025

Nifty (future)	
Resistance	26200
Support	25920

Bank Nifty (future)	
Resistance	59340
Support	58820

PROGRESSIVE'S EVENING STROLL **DATE: 17 November, 2025**

KEY TAKEAWAYS OF THE DAY

- **Godrej Properties to launch properties worth Rs22,000cr:**

The company has announced plans to launch housing units worth ~Rs22,000cr in the H2FY26. The company aims for an annual launch target of Rs40,000cr and sales bookings of Rs32,500cr.

- **Alembic Pharma received USFDA nod for Diltiazem Hydrochloride tablets:**

The company has received USFDA final approval for Diltiazem Hydrochloride Tablets, 30/60/90/120mg.

- **IRB Infrastructure Trust bags project from NHAI:**

The company has received an LoA from NHAI in Uttar Pradesh for a price consideration of Rs9,270cr for covering 366 km of the Lucknow-Ayodhya-Gorakhpur corridor on NH-27, and part of Lucknow-Varanasi corridor on NH-731, for a revenue linked concession period of 20 years.

- **Ola Electric rolls out test rides for indigenous 4680 bharat cell-powered scooters:**

The company has announced that it has commenced test rides of its 4680 Bharat Cell vehicles at the company's flagship stores across India. The S1 Pro+ (5.2kWh) is the first product to be powered by the company's Bharat Cell battery pack that delivers more range, and it has recently secured ARAI certification under the latest AIS-156 Amendment 4 standards issued by the Ministry of Road Transport and Highways.

- **Maruti Suzuki set to recall 39,506 units of Grand:**

The company had recalled approx. 39,506 Grand Vitara units after identifying an issue with the fuel level indicator and warning light in some vehicles. The affected units were manufactured between December 9, 2024, and April 29, 2025.

- **Divi's Laboratories clears USFDA Inspection with zero observations:**

The company's Unit-I facility at Telangana, has been inspected by the USFDA from 10-14th November, 2025. This inspection was a general cGMP inspection by the USFDA and was concluded with no 483 observation.

Source: Media Reports

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai—400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Neha Oza,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500.

Grievance Officer:
Email: grievancecell@progressiveshares.com